Show simple item record

dc.contributor.authorAl-Hammadi, Suleiman
dc.date.accessioned2023-05-08T07:07:12Z
dc.date.available2023-05-08T07:07:12Z
dc.date.issued2022
dc.identifier.other204-2022.165
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/1221
dc.description.abstractAbstract: Monogenic immune dysregulation diseases (MIDD) are caused by defective immunotolerance. This study was designed to increase knowledge on the prevalence and spectrum of MIDDs, genetic patterns, and outcomes in Middle East and North Africa (MENA). MIDD patients from 11 MENA countries (Iran, Turkey, Kuwait, Oman, Algeria, Egypt, United Arab Emirates, Tunisia, Jordan, Qatar, and Azerbaijan) were retrospectively evaluated. 343 MIDD patients (58% males and 42% female) at a median (IQR) age of 101 (42–192) months were enrolled. The most common defective genes were LRBA (23.9%), LYST (8.2%), and RAB27A (7.9%). The most prevalent initial and overall manifestations were infections (32.2% and 75.1%), autoimmunity (18.6% and 41%), and organomegaly (13.3% and 53.8%), respectively. Treatments included immunoglobulin replacement therapy (53%), hematopoietic stem cell transplantation (HSCT) (14.3%), immunosuppressives (36.7%), and surgery (3.5%). Twenty-nine (59.2%) patients survived HSCT. Along with infectious complications, autoimmunity and organomegaly may be the initial or predominant manifestations of MIDD.en_US
dc.language.isoenen_US
dc.subjectInborn Errors of Immunityen_US
dc.subjectPrimary Immunodeficiencyen_US
dc.subjectImmune Dysregulationen_US
dc.subjectAutoimmune Disordersen_US
dc.subjectLymphoproliferationen_US
dc.subjectGeneticen_US
dc.titleClinical, immunological, molecular and therapeutic findings in monogenic immune dysregulation diseases: Middle East and North Africa registryen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record